文献速递眼底病与葡萄膜炎

结膜下递送p75NTR拮抗剂可减轻糖尿病视网膜病变的炎症、血管和神经退行性病理改变

Subconjunctival Delivery of p75NTR Antagonists Reduces the Inflammatory, Vascular, and Neurodegenerative Pathologies of Diabetic Retinopathy.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2017-01-01

在链脲佐菌素糖尿病视网膜病变小鼠模型中,比较单次40 μg结膜下储库与5 μg玻璃体内注射THX-B的药代动力学和疗效;结膜下储库提供与玻璃体内注射相同的视网膜暴露且无全身药物检出,第2周时炎症、水肿和神经元死亡减少且视网膜结构获持久保护。

要点

  • 结膜下储库提供与玻璃体内注射相同的视网膜暴露,且循环中检测不到药物。
  • 糖尿病视网膜病变第2周,结膜下储库疗效与玻璃体内注射相似:炎症减轻、水肿减轻、神经元死亡减少。
  • 结膜下注射是p75NTR拮抗剂视网膜递送的安全有效途径,具有微创、依从性更好和非全身性的优势。

核心结论

  • 结膜下注射是视网膜递送p75NTR拮抗剂的安全有效途径,提供一种有优势、更微创、更依从且非全身性的方法来递送p75NTR拮抗剂以治疗视网膜疾病。

研究设计与样本

  • 在链脲佐菌素糖尿病视网膜病变小鼠模型中,比较单次40 μg结膜下储库与已报道有效的5 μg玻璃体内注射THX-B的药代动力学。
  • 以炎症、水肿和神经元死亡为终点量化治疗效果。

主要发现

  • 结膜下储库提供与玻璃体内注射相同的视网膜暴露,且循环中检测不到药物。
  • 糖尿病视网膜病变第2周,结膜下储库提供与玻璃体内注射相似的治疗效果,炎症减轻、水肿减轻、神经元死亡减少,并对视网膜结构有持久保护。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The p75NTR is a novel therapeutic target validated in a streptozotocin mouse model of diabetic retinopathy. Intravitreal (IVT) injection of small molecule p75NTR antagonist THX-B was therapeutic and resolved the inflammatory, vascular, and neurodegenerative phases of the retinal pathology. To simplify clinical translation, we sought a superior drug delivery method that circumvents risks associated with IVT injections. METHODS: We compared the pharmacokinetics of a single 40 μg subconjunctival (SCJ) depot to the reported effective 5 μg IVT injections of THX-B. We quantified therapeutic efficacy, with endpoints of inflammation, edema, and neuronal death. RESULTS: The subconjunctival depot affords retinal exposure equal to IVT injection, without resulting in detectable drug in circulation. At week 2 of diabetic retinopathy, the SCJ depot provided therapeutic efficacy similar to IVT injections, with reduced inflammation, reduced edema, reduced neuronal death, and a long-lasting protection of the retinal structure. CONCLUSIONS: Subconjunctival injections are a safe and effective route for retinal delivery of p75NTR antagonists. The subconjunctival route offers an advantageous, less-invasive, more compliant, and nonsystemic method to deliver p75NTR antagonists for the treatment of retinal diseases.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Galan A, Barcelona PF, Nedev H, et al. Subconjunctival Delivery of p75NTR Antagonists Reduces the Inflammatory, Vascular, and Neurodegenerative Pathologies of Diabetic Retinopathy. Invest Ophthalmol Vis Sci. 2017. PMID: 28570737. doi:10.1167/iovs.16-20988

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。